NGeneBio Co

NGeneBio Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is 153.05 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 98.44 % — a change of 55.48% (higher).

Cash Conversion

153.05 %

YoY

55.48%

Last updated:

Cash Conversion Rate (OCF/Net Income) of NGeneBio Co is 2025 153.05 % . Cash Conversion Rate (OCF/Net Income) of NGeneBio Co was 2024 98.44 % . It decreases by 55.48% higher compared to the previous year.

The NGeneBio Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
139.62 KRW
Jan 1, 2019
51.75 KRW
Jan 1, 2020
65.97 KRW
Jan 1, 2021
92.76 KRW
Jan 1, 2022
79.92 KRW
Jan 1, 2023
71.79 KRW
Jan 1, 2024
98.44 KRW
Jan 1, 2025
153.05 KRW
The NGeneBio Co Cash Conversion history
YEARCash ConversionYoY
153.05 %+55.48%
98.44 %+37.12%
71.79 %-10.17%
79.92 %-13.84%
92.76 %+40.59%
65.97 %+27.49%
51.75 %-62.93%
139.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Cash Conversion Rate (OCF/Net Income) of NGeneBio Co is 153.05 % in 2025.

Cash Conversion Rate (OCF/Net Income) of NGeneBio Co changed from 98.44 % to 153.05 %, representing a 55.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s NGeneBio Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NGeneBio Co

All Key Metrics — NGeneBio Co